Loading clinical trials...
Loading clinical trials...
A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients
Conditions
Interventions
VentaProst
Locations
3
United States
Stanford University Medical Center
Stanford, California, United States
Rush University Medical Center
Chicago, Illinois, United States
Tufts Medical Center
Boston, Massachusetts, United States
Start Date
August 23, 2017
Primary Completion Date
March 1, 2019
Completion Date
May 30, 2019
Last Updated
July 31, 2025
NCT05746039
NCT03854071
NCT07073820
NCT07477197
NCT06899815
NCT07462260
Lead Sponsor
Aerogen Pharma Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions